Repligen

USA-based Repligen Corp says data from a preclinical study demonstrate that its novel histone deacetylase inhibitor improved disease symptoms in a transgenic animal model of Huntington\'s disease.

Led by scientists at the Scripps Research Institute, the study demonstrated that oral administration of the drug candidate to the mice after the onset of symptoms slowed the progression of disease.

Treated animals showed superior motor performance by multiple measures, reduced loss of body weight, less brain atrophy and improved overall appearance compared to untreated animals.